Accueil   Diary - News   All news ERYTECH ANNOUNCES LAUNCH OF INVESTIGATOR-INITIATED PHASE 2 STUDY OF ERYASPASE (GRASPA®)

ERYTECH ANNOUNCES LAUNCH OF INVESTIGATOR-INITIATED PHASE 2 STUDY OF ERYASPASE (GRASPA®)

ERYTECH Pharma a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the launch of an investigator-initiated study to evaluate eryaspase, also known by the trade name GRASPA®, in patients with acute lymphoblastic leukemia (ALL). The study will take place in seven Nordic countries and be conducted in collaboration with the Nordic Society of Pediatric Hematology and Oncology (NOPHO).

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree